Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenpiprane SCHEMBL24507 | 0.89 | ALDH1A1 (0.66) | SIGMAR1CACNA1BALDH1A1 | |
| Prozapine SCHEMBL25765 | 0.89 | ALDH1A1 (0.66) | SIGMAR1CACNA1BALDH1A1 | |
| Prozapine SCHEMBL365642 | 0.87 | ALDH1A1 (0.64) | SIGMAR1ALDH1A1 | |
| Fenpiprane SCHEMBL11585426 | 0.87 | ALDH1A1 (0.64) | SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31220695 | 0.86 | SCN5A (0.75) | SIGMAR1SCN5AHRH3 | |
| Hydrochloric Acid SCHEMBL7250397 | 0.83 | SIGMAR1 (0.49) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5760954 | 0.83 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL11584567 | 0.82 | ACHE (0.62) | SIGMAR1ALDH1A1 | |
| SCHEMBL8447051 | 0.82 | SIGMAR1 (0.62) | SIGMAR1 | |
| SCHEMBL11196674 | 0.81 | SIGMAR1 (0.52) | SIGMAR1SCN5ACACNA1BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3364 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20240277729-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2024-08-22 | — | — | US | claimed |
| US-20230416782-A1 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | claimed |
| EP-4259207-A1 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2023-10-18 | — | — | EP | claimed |
| US-20230271142-A1 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | MICROPORE TECHNOLOGIES LIMITED (GB) | 2023-08-31 | — | — | US | claimed |
| EP-4188570-A2 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | Micropore Technologies Limited (GB) | 2023-06-07 | — | — | EP | claimed |
| WO-2022125784-A1 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-16 | — | — | WO | claimed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | claimed |
| US-20210228570-A1 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | PURDUE PHARMA LP (US) | 2021-07-29 | — | — | US | claimed |
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | claimed |
| US-20020111342-A1 | Methods for the inhibition of egg production in trematodes | THE INSTITUTE FOR ONEWORLD HEALTH | 2002-08-15 | — | — | US | claimed |
| WO-2002005821-A1 | METHODS FOR THE INHIBITION OF EGG PRODUCTION IN TREMATODES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001080837-A2 | TRANSDERMAL OR TRANSMUCOSAL DOSAGE FORMS WITH A NICOTINE-CONTAINING ACTIVE SUBSTANCE COMBINATION FOR SMOKER DISINTOXICATION | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2001-11-01 | — | — | WO | claimed |
| EP-0839026-B1 | POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS | SUPRATEK PHARMA INC (CA) | 2001-09-26 | — | — | EP | claimed |
| US-6153193-A | A MICELLE COMPRISING AN ANTITUMOR AGENT, A POLYETHER BLOCK COPOLYMER AND A TARGETING MOLECULE COMPRISING A LIPOPHILIC HYDROCARBON MOIETY HAVING 3 TO ABOUT 41 CARBON ATOMS | SUPRATEK PHARMA INC. (CA) | 2000-11-28 | — | — | US | claimed |
| US-6100256-A | ORALLY ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT NK-1(NEUROKININ-1, SUBSTANCE P) RECEPTOR ANTAGONIST; FOR PATIENT WHO IS NON-RESPONSIVE TO, OR FOR WHOM ANTIPSYCHOTIC AGENTS ARE CONTRAINDICATED | MERCK SHARP & DOHME LTD. (GB) | 2000-08-08 | — | — | US | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| EP-0839026-A1 | POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS | SUPRATEK PHARMA, INC. (CA) | 1998-05-06 | — | — | EP | claimed |
| WO-1996040056-A1 | POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS | SUPRATEK PHARMA INC. (CA) | 1996-12-19 | — | — | WO | claimed |